She Used Red Light Therapy for a Few Week. Then Her Macular Hole Opened. Here's What Every Patient Needs to Know.
A Patient's Concern: When Red Light Therapy Coincided with Macular Hole Progression
A 71-year-old woman recently visited my office with an alarming story. For years, she had been living with an impending macular hole that remained stable under careful observation. However, approximately a few weeks after beginning red light therapy applying it at times to her lower eyelids without red light glasses because she couldn't find the ones that came with the machine, she noticed a dramatic change—the hole opened, and her vision significantly decreased. Understandably, she wondered whether there was a connection between the new therapy and her sudden vision loss.
This case raises important questions about the safety of red light therapy, particularly for individuals with pre-existing macular pathology. While red light therapy has gained popularity for various health applications, the relationship between this treatment and retinal health—especially in vulnerable eyes—deserves careful examination.
What Is Red Light Therapy and How Does It Work?
Red light therapy, also known as photobiomodulation (PBM) or low-level light therapy, uses specific wavelengths of red and near-infrared light (typically 620-1000 nm) to stimulate cellular processes. The therapy works primarily through absorption of photons by mitochondrial cytochrome C oxidase, a key enzyme in cellular energy production.[1][2][3]
When red or near-infrared light is absorbed by this enzyme, several beneficial cellular changes occur: increased production of adenosine triphosphate (ATP), modulation of reactive oxygen species, alterations in intracellular calcium levels, and activation of various signaling pathways that promote cellular proliferation, migration, and differentiation.[1] The therapy also dissociates inhibitory nitric oxide from cytochrome C oxidase, restoring electron transport and improving mitochondrial function.[2][3]
Established Medical Uses of Red Light Therapy
Red light therapy has demonstrated efficacy across multiple medical disciplines:
Wound Healing and Tissue Repair: Red light therapy significantly promotes wound healing by upregulating collagen synthesis (COL1A1, COL2A1), enhancing VEGF-mediated angiogenesis, and reducing inflammatory markers like IL-1β.[4] Studies show that red light (630-680 nm) and near-infrared light (800-830 nm) accelerate wound closure, increase tissue thickness, and promote fibroblast and endothelial cell proliferation.[5][6]
Dermatologic Applications: The therapy is used for skin rejuvenation, acne vulgaris treatment, and management of photoaging. Blue light (400-470 nm) targets acne through antibacterial effects, yellow light (570-590 nm) reduces melasma by suppressing melanogenesis, and red light promotes collagen synthesis and skin rejuvenation.[7]
Pain and Inflammation Management: PBM therapy reduces pain, inflammation, and edema while promoting regeneration of damaged tissues including bones and tendons.[3]
Cancer Treatment Support: Photobiomodulation effectively prevents oral mucositis in patients receiving cancer treatment by restoring ATP production, reducing oxidative stress, and enabling faster cellular recovery.[8]
Musculoskeletal Conditions: The therapy has shown benefits for various musculoskeletal disorders through its anti-inflammatory and tissue regeneration properties.[8][1]
Red Light Therapy for Meibomian Gland Dysfunction and Dry Eye
One of the most promising ophthalmic applications of red light therapy is in treating meibomian gland dysfunction (MGD) and dry eye disease. Multiple studies have demonstrated significant benefits:
Low-level light therapy (LLLT) using 633 nm red light for 15 minutes per session significantly improved dry eye symptoms, tear meniscus height, tear film lipid layer thickness, and eyelid temperature in patients with mild to moderate dry eye.[9] The treatment increased tear meniscus height by 0.06 mm and tear film lipid layer thickness by 12.9 nm, while reducing symptom scores by 10.2 points.[9]
When comparing LLLT to intense pulsed light (IPL) for MGD treatment, both therapies were safe and effective, but LLLT demonstrated greater improvement in ocular discomfort symptoms and tear volume.[10] A combined therapy approach using IPL with LLLT showed significant improvement in tear break-up time and symptom scores compared to controls.[11]
A recent study using a 675 nm laser system (RedTouch laser) found that direct targeting of the meibomian glands and lid margin produced superior outcomes compared to periocular treatment alone, with significant improvements in all dry eye parameters and meibomian gland signs.[12] Animal studies have confirmed that multi-wavelength LED irradiation (680 nm, 780 nm, 830 nm) reduces inflammatory cytokines and improves MGD-induced dry eye disease.[13]
Red Light Therapy and the Retina: Promise and Concerns
The application of red light therapy to retinal conditions presents a complex picture of potential benefits and emerging safety concerns.
Potential Benefits for Retinal Conditions
Red light therapy has been investigated for age-related macular degeneration (AMD), myopia control, glaucoma, diabetic retinopathy, and other retinal diseases.[14][15] The proposed mechanisms include enhancing mitochondrial activity, reducing oxidative damage, decreasing inflammatory mediators, and improving retinal function.[16]
For non-exudative AMD, photobiomodulation using wavelengths of 590 nm, 660 nm, and 850 nm has been studied in clinical trials. However, a 2021 Cochrane review found only low to very low-quality evidence that PBM made little or no difference to visual acuity or disease progression after one year of treatment.[16] Some case series reported improvements in visual acuity, contrast sensitivity, and drusen volume, but these findings require confirmation in larger, well-designed trials.[16]
Emerging Safety Concerns
Independent safety evaluations of commercially available red light devices revealed that several laser-based instruments (EyeRising, Sky-n1201) exceeded American National Standards Institute (ANSI) safety limits within exposure times below the recommended 180-second treatment duration.[18] These findings led to regulatory reclassification of red laser devices as Class III medical devices in China.[18]
A 2025 review emphasized that while red light therapy shows promise for various ocular conditions, "questions regarding optimal dosing, safety, and standardization remain pressing" and "long-term effects and safety need careful evaluation".[14]
Could Red Light Therapy Cause or Worsen Macular Holes?
This is the critical question for my patient and others with pre-existing macular pathology. Based on current published literature, there is no direct evidence that red light therapy causes macular holes or accelerates their progression from an impending to a full-thickness state.
What We Know About Macular Hole Formation: Macular holes develop primarily due to tractional forces at the vitreoretinal interface during posterior vitreous detachment. The pathogenesis involves anteroposterior and tangential traction exerted by the vitreous on the fovea, leading to intraretinal cyst formation and eventual full-thickness defect.[19] Risk factors include age (typically sixth or seventh decade), female gender (3:1 ratio), myopia, and trauma.[20][21]
The Absence of Evidence: In the extensive literature on photobiomodulation for retinal conditions, including studies on AMD, myopia, and other macular diseases, there are no published case reports or clinical trial data specifically linking red light therapy to macular hole formation or progression.[16][15][22][23]
Theoretical Considerations: The safety concerns that have emerged relate primarily to photoreceptor damage (cone density loss) and drusen-like changes in children receiving high-dose laser therapy for myopia.[17] These findings suggest potential for photothermal or photochemical retinal injury, particularly with laser-based devices that exceed safety standards.[18] However, the mechanism of such injury differs fundamentally from the mechanical tractional forces that cause macular holes.
The Temporal Coincidence: In my patient's case, the timing—macular hole opening one week after starting red light therapy—may represent coincidence rather than causation. Impending macular holes can progress spontaneously, and the natural history of stage 1 macular holes includes progression to full-thickness holes in a significant proportion of cases without any intervention.[21]
Clinical Recommendations and Cautions
Given the current state of evidence, several important considerations emerge:
Device Selection Matters: LED-based photobiomodulation devices appear safer than laser-based systems, as they produce diffuse illumination and remain within safety limits for extended exposures.[18] Laser-based devices, particularly those used for myopia control, have been shown to exceed safety standards and should be avoided without rigorous independent validation.[18]
Standardization and Dosimetry: The field lacks international consensus on optimal dosing parameters, and treatment protocols vary widely across studies.[14] Parameters including wavelength, power density, treatment duration, and distance from the eye all significantly impact biological effects and safety.[4][5]
Monitoring and Follow-up: Any patient using red light therapy for ocular conditions should undergo regular comprehensive eye examinations, including high-resolution retinal imaging. Traditional outcome measures like visual acuity and standard OCT may be insufficient to detect early photoreceptor damage; advanced imaging such as adaptive optics may be necessary.[18]
Regulatory Status: The regulatory landscape is evolving, with some jurisdictions reclassifying red light devices as higher-risk medical devices requiring stricter oversight.[18] Patients should verify that any device they use has appropriate regulatory approval and independent safety validation.
Conclusion: Balancing Promise with Prudence
Red light therapy represents a promising therapeutic modality with established benefits for wound healing, dermatologic conditions, pain management, and meibomian gland dysfunction. Its applications in ophthalmology, particularly for dry eye disease, show genuine clinical value with good safety profiles when appropriate devices and protocols are used.
However, for retinal applications—especially in patients with pre-existing macular pathology—the evidence base remains incomplete, and emerging safety concerns warrant caution. While there is no published evidence directly linking red light therapy to macular hole formation or progression, the absence of evidence is not evidence of absence, particularly given the recent findings of photoreceptor damage in some patient populations.
For my patient with the impending macular hole that progressed after starting red light therapy, the most likely explanation is spontaneous progression according to the natural history of her condition. However, given the uncertainties and emerging safety data, I would recommend discontinuing red light therapy directed at the eyes and maintaining close ophthalmologic surveillance.
As the field continues to evolve, rigorous, independent clinical trials with long-term safety monitoring, standardized protocols, and appropriate patient selection criteria will be essential to fully realize the therapeutic potential of photobiomodulation while protecting patient safety.
📊 Chart 1: Red Light Therapy for Dry Eye Disease & MGD
Published studies showing benefits of red/near-infrared light for dry eye and meibomian gland dysfunction
| Study (Year) | Device / Light Source | Wavelength (nm) | Duration / Protocol | Key Outcomes |
|---|---|---|---|---|
| Antwi et al. (2024)[9] | LED-based LLLT device | 633 nm (red) | 15 min/session | Tear meniscus height ↑0.06 mm; lipid layer thickness ↑12.9 nm; symptom scores ↓10.2 pts; eyelid temp ↑ |
| Giannaccare et al. (2023)[10] | LED-based LLLT vs. IPL | 633 nm (LLLT arm) | Multiple sessions (prospective RCT) | Both LLLT and IPL safe/effective for MGD; LLLT showed greater improvement in ocular discomfort and tear volume |
| D'Souza et al. (2023)[11] | IPL + LLLT combination | IPL broadband + LLLT red | Randomized controlled study | Combined IPL + LLLT significantly improved tear break-up time and symptom scores vs. controls |
| Vergés et al. (2025)[12] | RedTouch Laser (Deka) | 675 nm (red laser) | Direct meibomian gland + lid margin targeting | Direct gland targeting superior to periocular alone; significant improvement in all dry eye parameters and MG signs |
| Kim et al. (2026)[13] | Multi-wavelength LED device | 680 nm, 780 nm, 830 nm | Animal model (rat MGD) | Reduced inflammatory cytokines; improved MGD-induced dry eye disease |
📊 Chart 2: Red Light Therapy for Wound Healing
Published evidence on photobiomodulation for tissue repair and wound closure
| Study (Year) | Device / Light Source | Wavelength (nm) | Duration / Protocol | Key Outcomes |
|---|---|---|---|---|
| Kuppa et al. (2025)[4] | Red-Light LED device | Red LED (specific nm not stated; red range) | LED irradiation protocol | Upregulated COL1A1, COL2A1, VEGF; reduced IL-1β; promoted wound regeneration and anti-inflammatory effects |
| Li et al. (2016)[5] | Red and Blue LED | Red: 630-680 nm; Blue: 400-470 nm | Rabbit skin wound model | Red LED accelerated wound closure, increased tissue thickness, promoted fibroblast and endothelial cell proliferation |
| Yadav & Gupta (2017)[6] | Red and NIR light sources | Red: 630-680 nm; NIR: 800-830 nm | Various impaired wound models | Promoted cutaneous wound healing in impaired conditions; enhanced angiogenesis, fibroblast activity, and re-epithelialization |
📊 Chart 3: Red Light Therapy for Age-Related Macular Degeneration (AMD)
Published studies investigating photobiomodulation for non-exudative AMD
| Study (Year) | Device / Light Source | Wavelength (nm) | Duration / Protocol | Key Outcomes |
|---|---|---|---|---|
| Henein & Steel, Cochrane Review (2021)[16] | Various PBM devices (multi-trial review) | 590 nm, 660 nm, 850 nm | Varied across included trials; up to 1 year follow-up | Low to very low-quality evidence; PBM made little or no difference to VA or disease progression at 1 year |
| Grewal et al. (2020)[22] | 670 nm PBM device | 670 nm (red) | Pilot study in healthy aging + AMD | Some improvements in visual acuity, contrast sensitivity, and drusen volume reported in case series; needs larger trials |
| Siqueira (2024)[15] | LED-based PBM (review) | Various (590-850 nm range) | Review of multiple protocols | PBM investigated for AMD, diabetic retinopathy, glaucoma; mechanisms include enhanced mitochondrial activity and reduced oxidative damage |
| Xue & Zhou (2025)[14] | Various (comprehensive review) | Various red/NIR wavelengths | Review article | Promise for multiple ocular conditions but "questions regarding optimal dosing, safety, and standardization remain pressing" |
📊 Chart 4: Red Light Therapy for Skin Rejuvenation
Light-based therapies used in cosmetic dermatology
| Light Color | Wavelength (nm) | Primary Dermatologic Application | Mechanism of Action | Reference |
|---|---|---|---|---|
| Red Light | 620-700 nm | Skin rejuvenation, collagen production, anti-aging | Stimulates fibroblast proliferation, upregulates collagen synthesis, enhances cellular metabolism | Guo & Yuan (2025)[7] |
| Blue Light | 400-470 nm | Acne vulgaris treatment | Antibacterial effect via porphyrin photoactivation in P. acnes bacteria | Guo & Yuan (2025)[7] |
| Yellow Light | 570-590 nm | Melasma, hyperpigmentation | Suppresses melanogenesis, reduces melanin production | Guo & Yuan (2025)[7] |
| Near-Infrared (NIR) | 800-1000 nm | Deep tissue rejuvenation, wound healing | Penetrates deeper into dermis; promotes tissue repair, reduces inflammation | Yadav & Gupta (2017)[6] |
📊 Chart 5: IPL vs. Low-Level Light Therapy vs. Red Light Therapy — What's the Difference?
These three treatments are often confused. Here is a clear comparison.
IPL
Intense Pulsed Light
Broad spectrum: 500-1200 nm
High-energy pulsed flashes
Targets blood vessels, pigment, inflammation
Requires trained operator
FDA-cleared devices (e.g., Lumenis M22, OptiLight)
LLLT
Low-Level Light Therapy
Single wavelength: 630-670 nm typical
Low power, continuous or pulsed
Targets mitochondria (cytochrome C oxidase)
Often LED-based masks/panels
Used in clinical and home settings
Red Light Therapy
Photobiomodulation (PBM)
620-1000 nm (red + near-infrared)
LED or laser-based
Broader term encompassing LLLT
Consumer panels, wands, masks
Variable quality and regulation
| Feature | IPL (Intense Pulsed Light) | LLLT (Low-Level Light Therapy) | Red Light Therapy / PBM |
|---|---|---|---|
| Light Type | Broadband, polychromatic (500-1200 nm) | Single wavelength, monochromatic (usually 630-670 nm) | Red + near-infrared (620-1000 nm); LED or laser |
| Energy Level | High energy, intense pulsed flashes | Low energy, continuous or gentle pulsed | Low to moderate energy |
| Primary Mechanism | Selective photothermolysis (heats targeted tissue: blood vessels, pigment, inflammatory cells) | Photobiomodulation via cytochrome C oxidase activation in mitochondria | Same as LLLT (mitochondrial activation, ATP production, ROS modulation) |
| Tissue Effect | Thermal destruction of abnormal blood vessels; reduces Demodex, inflammation; melts meibum | Non-thermal; stimulates cellular repair, reduces inflammation at the cellular level | Primarily non-thermal; some laser devices can produce thermal effects |
| Dry Eye / MGD Use | Targets lid/periocular blood vessels and inflammation; FDA-cleared for dry eye (OptiLight) | Improves tear film, meibomian gland function, reduces symptoms[9][10] | Broad category; includes both LLLT protocols and laser-based approaches (e.g., RedTouch)[12] |
| Safety Profile | Requires eye shields; risk of burns if misapplied; requires trained professional | Generally very safe; LED-based; minimal risk of tissue damage | LED devices safer; laser devices may exceed ANSI safety limits[18] |
| Regulation | FDA-cleared medical devices; requires professional use | Some FDA-cleared; many OTC consumer devices | Variable; some devices reclassified as Class III in China[18] |
| Typical Setting | Doctor's office only | Clinical or home use | Clinical or home use (quality varies widely) |
References
- Maghfour J, Ozog DM, Mineroff J, et al. Photobiomodulation CME Part I: Overview and Mechanism of Action. Journal of the American Academy of Dermatology. 2024;91(5):793-802. doi:10.1016/j.jaad.2023.10.073.
- de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417. doi:10.1109/JSTQE.2016.2561201.
- Hamblin MR. Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. Photochem Photobiol. 2018;94(2):199-212. doi:10.1111/php.12864.
- Kuppa SS, Kang JY, Kim JY, et al. Red-Light LED Therapy Promotes Wound Regeneration by Upregulating COL1A1, COL2A1, VEGF and Reducing IL-1β. Lasers Med Sci. 2025;40(1):171. doi:10.1007/s10103-025-04432-9.
- Li Y, Zhang J, Xu Y, et al. The Histopathological Investigation of Red and Blue LED on Treating Skin Wounds in Japanese Big-Ear White Rabbit. PLoS One. 2016;11(6):e0157898. doi:10.1371/journal.pone.0157898.
- Yadav A, Gupta A. Noninvasive Red and Near-Infrared Wavelength-Induced Photobiomodulation: Promoting Impaired Cutaneous Wound Healing. Photodermatol Photoimmunol Photomed. 2017;33(1):4-13. doi:10.1111/phpp.12282.
- Guo Z, Yuan K. The Application of Light Emitting Diode (LED) in Cosmetic Dermatology. Photodermatol Photoimmunol Photomed. 2025;41(5):e70041. doi:10.1111/phpp.70041.
- Lewis SR, Riley P, Deligianni E, et al. Interventions for Preventing Oral Mucositis in People Receiving Cancer Treatment: Photobiomodulation. Cochrane Database Syst Rev. 2024;12:CD016068. doi:10.1002/14651858.CD016068.
- Antwi A, Schill AW, Redfern R, Ritchey ER. Effect of Low-Level Light Therapy in Individuals With Dry Eye Disease. Ophthalmic Physiol Opt. 2024;44(7):1464-1471. doi:10.1111/opo.13371.
- Giannaccare G, Pellegrini M, Carnovale Scalzo G, et al. Low-Level Light Therapy Versus Intense Pulsed Light for the Treatment of Meibomian Gland Dysfunction. Cornea. 2023;42(2):141-144. doi:10.1097/ICO.0000000000002997.
- D'Souza S, James E, Koul A, et al. A Randomized Controlled Study Evaluating Outcomes of IPL and LLLT for Treating MGD and Evaporative Dry Eye. Indian J Ophthalmol. 2023;71(4):1608-1612. doi:10.4103/IJO.IJO_2834_22.
- Vergés C, Ribas V, Salgado-Borges J, et al. Prospective Evaluation of RedTouch Laser in the Treatment of Dry Eye Disease Secondary to MGD. Clin Ophthalmol. 2025;19:1731-1742. doi:10.2147/OPTH.S519700.
- Kim H, Shin C, Lee S, Cho K. Therapeutic Efficacy and Safety of a Multi-Wavelength LED Irradiation Device in a Rat Model of MGD. Lasers Med Sci. 2026;41(1):50. doi:10.1007/s10103-026-04813-8.
- Xue F, Zhou Y. Illuminating Eye Care: The Promise and Future of Red Light Therapy in Ophthalmology. Graefes Arch Clin Exp Ophthalmol. 2025;263(6):1515-1522. doi:10.1007/s00417-025-06800-1.
- Siqueira RC. Photobiomodulation Using LED for Treatment of Retinal Diseases. Clin Ophthalmol. 2024;18:215-225. doi:10.2147/OPTH.S441962.
- Henein C, Steel DH. Photobiomodulation for Non-Exudative Age-Related Macular Degeneration. Cochrane Database Syst Rev. 2021;5:CD013029. doi:10.1002/14651858.CD013029.pub2.
- Liao X, Yu J, Fan Y, et al. Cone Density Changes After Repeated Low-Level Red Light Treatment in Children With Myopia. JAMA Ophthalmol. 2025;143(6):480-488. doi:10.1001/jamaophthalmol.2025.0835.
- Ostrin LA, Schill AW. Safety Evaluation of 4 Red Light Therapy Devices for Myopia. JAMA Ophthalmol. 2026;:2844586. doi:10.1001/jamaophthalmol.2025.5660.
- Cundy O, Lange CA, Bunce C, et al. Face-Down Positioning After Macular Hole Surgery. Cochrane Database Syst Rev. 2023;11:CD008228. doi:10.1002/14651858.CD008228.pub3.
- Ghoraba H, Rittiphairoj T, Akhavanrezayat A, et al. Vitrectomy With ILM Flap Versus Conventional ILM Peeling for Large Macular Hole. Cochrane Database Syst Rev. 2023;8:CD015031. doi:10.1002/14651858.CD015031.pub2.
- Parravano M, Giansanti F, Eandi CM, et al. Vitrectomy for Idiopathic Macular Hole. Cochrane Database Syst Rev. 2015;(5):CD009080. doi:10.1002/14651858.CD009080.pub2.
- Grewal MK, Sivapathasuntharam C, Chandra S, et al. A Pilot Study Evaluating Effects of 670 nm PBM in Healthy Ageing and AMD. J Clin Med. 2020;9(4):E1001. doi:10.3390/jcm9041001.
- Tan NRX, Chan KE, Lim BXH, et al. Photobiomodulation: Evidence and Applications in Ophthalmology. Curr Opin Ophthalmol. 2025;:00055735-990000000-00249. doi:10.1097/ICU.0000000000001154.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.